The purpose of this project is to understand how different e-cigarettes influence their likeability and use among current smokers who try using e-cigarettes. Participants will receive an e-cigarette to sample over a three week period. During this time period they will complete daily electronic diaries and weekly lab visits. The results from this information will help us understand how different types of e-cigarettes are likely to influence cigarette and e-cigarette use.
This is a research study to find out if a smoking cessation medication, varenicline, is effective when given to smokers, remotely, as a one-time, 4-week sample.
Participants will either receive a sample of varenicline, or not. This will be decided randomly. The medicine will be mailed to participants and participants will complete 7 study contacts in addition to completing daily diaries for the first 4 weeks of the study. Participation will last 3 months.
Varenicline is a well-established medication that helps smokers quit. If participants are in the group that receives varenicline, it may help them too. But they are not required to use it, and it is completely up to them to use as they wish. Side effects from taking varenicline might include insomnia, headache, or nausea. Some individuals report negative changes in mood. Most smokers who use varenicline do not experience these symptoms.
The goal of this study is to develop, refine, and complete preliminary feasibility testing of a smoking cessation electronic visit (e-visit) for implementation in primary care/family medicine. We will conduct a feasibility RCT (n=90) of the smoking cessation e-visit as compared to treatment as usual (TAU), delivered via primary care, with primary objective to provide effect size estimates for a larger RCT. Primary outcomes cluster around: 1) treatment feasibility, 2) treatment acceptability, 3) treatment satisfaction, 4) evidence-based cessation treatment utilization, and 5) cessation-related outcomes (quit attempt incidence, abstinence). We hypothesize that participants randomized to the e-visit condition as compared to those randomized to the TAU condition will have higher rates of cessation treatment utilization (medications, counseling) and superior cessation-related outcomes.
The proposed study is looking to recruit smokers over the age of 18 to complete a four visit study. Participants will be randomized to receive either rapamycin (sirolimus) or a placebo at the second visit to assess potential effects on craving and relapse. Four study visits will be completed over the course of about three weeks.
MUSC is recruiting adult cigarette smokers (18 to 65) who are interested in participating in a research study examining the effects of brain stimulation on neural activity and behavior. This study consists of 2 visits over the course of 1-2 weeks. Qualified individuals will be compensated for participation. This research study is sponsored by MUSC but will physically take place at USC in Columbia, SC.
The first week after attempting to quite cigarette smoking is the hardest period to succeed. Research shows that individuals able to remain cigarette free for this first week are significantly more likely to quit the smoking habit. In this study, sponsored by the National Institutes of Health, we are evaluating a new tool to assist individuals with quitting cigarette smoking. Transcranial magnetic stimulation (TMS) is a non-invasive technique that uses magnetic pulses to temporarily stimulate specific brain areas (without the need for surgery, anesthetic, or other invasive procedures). This study will test whether 10 daily sessions of TMS over the forehead can help decrease smoking rates in treatment-seeking individuals.
The purpose of this study is to develop theta burst transcranial magnetic stimulation (tbTMS) as a potential treatment for nicotine addiction. Theta burst TMS is a non-invasive technique that uses magnetic pulses to temporarily stimulate specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). This study will test whether tbTMS over the forehead can produce a reduction in things that may prompt you to want to smoke cigarettes. TMS has been approved by the Food and Drug Administration as an investigational tool as well as a therapy for depression. However, TMS is not approved by the Food and Drug Administration as a treatment for nicotine cravings and other addictions.
This study consists of one consent session and one TMS session (can be on same day). Subjects will be asked to complete a series of questionnaires and computer assessments on how you think about nicotine and one session of TMS will be completed.
Current cigarette smokers (N=40) will sample three e-liquids within a single lab session, with different PG/VG ratios, complete a battery of questionnaires to assess sensory characteristics, product appeal, and reinforcement value. Participants will then complete a lab-based preference task to assess reinforcement value in which they choose between the three e-liquids. Finally, participants will receive one of the three e-liquids to take home for a one-week sampling period. During that week, we will assess e-cigarette and cigarette use. Participants will return the lab at the end of the week to complete additional questionnaires and return any unused product.
Cigarette smoking is a significant public health concern especially in cancer patients. rTMS has been investigated for smoking cessation in healthy smokers. This study will test the therapeutic benefits of rTMS for smoking cessation in cancer patients with smoking. Firstly, we will evaluate total number of smoke-free days during a 7-day quit attempt. Secondly, we will evaluate cigarette consumption and cue craving for smoking during the quit attempt period.
We recently published results from a NIDA-funded study of a brief behavioral treatment that was designed to reduce the troublesome cravings that smokers encounter when they attempt to quit smoking. This intervention was based on a growing body of neuroscience studies showing that memories for prior learning can be retrieved by the presentation of cues involved in that learning. Once retrieved, the memories enter into a brief period of vulnerability, during which they can be modified, but after which they are reconsolidated (restabilized) back into long-term storage. The treatment potential of this phenomenon was initially demonstrated in a Science report in which inpatient heroin addicts were briefly exposed to cues associated with heroin use in order to prompt the heroin use memories into a vulnerable state. Once the memories were in this state, the heroin addicts received extinction training consisting of protracted exposure to heroin associated cues. It was argued that extinction would change the memories such that the cues would no longer be associated with heroin administration and reward. Remarkably, after just two sessions of retrieval-extinction training (RET), the investigators found that craving in response to heroin cues was substantially reduced for up to 6-months post-treatment. This effect was observed relative to a control group that received retrieval involving non-heroin cues, followed by extinction. These impressive initial findings led us to replicate and extend the study in cigarette smokers. In our study, one group of smokers received two sessions of RET with smoking cues whereas a control group received the same training except that retrieval consisted of brief exposure to neutral, smoking-unrelated cues. Craving and other reactions to familiar and novel smoking cues were assessed in test sessions performed 24-hrs, 2-weeks and 1-month after intervention; smoking behavior was also assessed over 1-month follow-up. Remarkably, at 1-month follow-up, craving to both familiar and novel smoking cues was significantly lower in the group receiving R-E training vs. control. Even more striking was the 25% reduction in the number of cigarettes smoked per day in the RET group vs. control. [Also of significance was suggestive evidence that, relative to control participants, more participants in the RET group achieved a 60% reduction in smoking (from pretreatment levels)]. The proposed project will replicate and extend these findings by 1) increasing the dose of intervention so as to bolster the observed treatment effects, 2) employing brain imaging methods to identify patterns of brain activity uniquely associated with the intervention and potentially predictive of treatment outcome, 3) adding a control group that will enhance understanding of the effects of RET, and 4) extending follow-up period to more completely document the long-term effects of RET. Positive findings from this study could lead to the development of a brief, effective behavioral intervention to reduce the burden levied against society by smoking. Importantly, this intervention could be easily adapted to treat other forms of addiction and co-occurring anxiety disorders, such as PTSD.